We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis.
- Authors
Hu, Marie; Goyal, Gaurav; Abeykoon, Jithma P.; Acosta-Medina, Aldo A.; Ruan, Gordan J.; Young, Jason R.; Ravindran, Aishwarya; Bennani, N. Nora; Shah, Mithun V.; Vassallo, Robert; Ryu, Jay H.; Davidge-Pitts, Caroline J.; Koster, Matthew J.; Tobin, W. Oliver; Sartori-Valinotti, Julio C.; Rech, Karen L.; Go, Ronald S.
- Abstract
Four patients required third-line treatment, and only one patient underwent fourth-line treatment. At last follow-up, 28 patients remained classified as unifocal, 6 patients were reclassified as single-system multifocal (4 bone, 2 skin), and 5 patients were reclassified as multisystem disease (Figs. Dear Editor, Langerhans cell histiocytosis (LCH) is a rare hematologic disorder affecting adults with an estimated incidence of 1-2 cases per million [[1]]. After discovery of I BRAF V600E i and I MAP2K1 i gain-of-function mutations in >70% of LCH patients, LCH was reclassified as an inflammatory myeloid neoplasm in the 2016 Histocyte Society classification [[4]-[6]].
- Subjects
LANGERHANS-cell histiocytosis; GROIN pain; DIABETES insipidus; TREATMENT effectiveness
- Publication
Blood Cancer Journal, 2022, Vol 12, Issue 6, p1
- ISSN
2044-5385
- Publication type
Article
- DOI
10.1038/s41408-022-00685-7